Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Truvada opvejer risiciene til antiretroviral kombinationsbehandling af hiv- 1- smittede voksne.
The Committee for Medicinal products for Human Use (CHMP) concluded that Truvada’ s benefits are greater than its risks in antiretroviral combination therapy for the treatment of HIV-1 infected adults.